PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of springeropenLink to Publisher's site
Cancer Chemotherapy and Pharmacology
 
From:
Published online 2017 August 5. doi: 10.1007/s00280-017-3387-5

Table 1

Summary of antiemetic efficacy of pharmaceutical cannabinoids in patients with CINV

TreatmentsStudies, n (no. of patients)Statistical significance of treatments
Resolution of nausea and vomiting, RR (95% CI)Resolution of nausea, RR (95% CI)Resolution of vomiting, RR (95% CI)
Dronabinol or nabilone vs prochlorperazine [25]9 (n = 1221)2.0 (0.7–5.4)1.5 (0.7–3.2)1.1 (0.9–1.4)
Dronabinol vs prochlorperazine [23]5 (n = 325)0.7 (0.5–1.0); P = 0.03; NNT = 3.4NRNR
Nabilone vs prochlorperazine, alizapride, or domperidone [23]6 (n = 277)0.9 (0.7–1.1); P = 0.2NRNR
Dronabinol or nabilone vs prochlorperazine or alizapride [24]13 (n = 422)NR1.4 (1.2–1.6); NNT = 6.41.3 (1.1–1.5); NNT = 8.0

Data presented for oral cannabinoids approved in the US for the treatment of CINV (i.e., dronabinol and nabilone)

CI confidence interval, CINV chemotherapy-induced nausea and vomiting, NNT number needed to treat, NR not reported, RR relative risk